Brexanolone produces ‘meaningful reductions’ in postpartum depression

October 05, 2018 8:15 AM | Anonymous

October 5, 2018, Healio  

Most women who received an injection of brexanolone — a positive allosteric modulator of -aminobutyric-acid type A receptors — for postpartum depression had significant and clinically meaningful reductions of the condition at 60 hours vs. placebo, according to findings recently published in The Lancet. 

Read more.

Powered by Wild Apricot Membership Software